^
Association details:
| Biomarker: | BCR-ABL1 Y253H |
|---|---|
| Cancer: | Chronic Myeloid Leukemia |
| Drug: | imatinib (c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor, PDGFR inhibitor) + Tasigna (nilotinib) (Bcr-abl tyrosine kinase inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)–based mutagenesis screen: high efficacy of drug combinations
Excerpt:
Compared with single agents, each of the 3 combinations (imatinib mesylate + nilotinib, imatinib mesylate + dasatinib, and nilotinib + dasatinib) was more effective at reducing the outgrowth of resistant cell clones (Figure 3)In all cases, a more profound suppression of growth was observed with the combinations as compared with single agents. Sequencing revealed only T315I in resistant clones, with the exception of the lowest concentrations of imatinib mesylate (400 nM) and nilotinib (50 nM), whereby F359C and Y253H were recovered in addition to T315I (Table S2).
DOI:
10.1182/blood-2006-02-004580
